TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12067856
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg testosterone enanthate (TE) weekly
Study: 12067856
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg testosterone enanthate (TE) weekly
Study: 20562752
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg sertraline per day
Study: 19633103
Drug: Darbepoetin alfa
Normalized name: Darbepoetin Alfa
DrugBank: Darbepoetin alfa (DB00012)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Darbepoetin alfa (subcutaneous administration, dosed to achieve Hb concentration of 13.0 g/dL, not exceeding 14.5 g/dL)
Study: 19633103
Drug: Placebo (subcutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (subcutaneous administration, sham adjustments of the dose)
Study: 11774820
Drug: Thymopentin (TP-5)
Normalized name: thymopentin
DrugBank: Thymopentin (DB11996)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thymopentin (TP-5) 1 mg/d for 20 days starting on 2 PBD
Study: 8381187
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy with cyclophosphamide, doxorubicin, and cisplatin (CAP) - 400 mg/m2 cyclophosphamide, 40 mg/m2 doxorubicin, 60 mg/m2 cisplatin, administered in four courses at 3-week intervals starting 30 days post-surgery.
Study: 8381187
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no adjuvant chemotherapy).
Study: 3116821
Drug: NORPLANT‐2 implants
Approvals — FDA: no, EMA: no, PMDA: no
Description: NORPLANT‐2 implants
Study: 3116821
Drug: NORPLANT and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: NORPLANT and NORPLANT‐2 implants
Study: 1608407
Drug: Phenytoin treatment
Normalized name: Phenytoin
DrugBank: Phenytoin (DB00252)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Phenytoin treatment
Study: 27792961
Drug: Cognitive-coping therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-coping therapy (CCT)
Study: 27792961
Drug: Pharmacotherapy plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacotherapy plus CCT (pCCT)
Study: 26431718
Drug: Inhaled nitric
Normalized name: nitric oxide Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled nitric oxide (iNO) 80 ppm for 3 days
Study: 26431718
Drug: Inhaled nitric
Normalized name: nitric oxide Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled nitric oxide (iNO) for patients with hypoxemia
Study: 26431718
Drug: Inhaled nitrogen
Normalized name: nitrogen Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled nitrogen placebo for patients with hypoxemia
Study: 11473953
Drug: Metformin 500
Normalized name: metformin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin 500 mg three times a day for 3 months
Study: 9608770
Drug: optimal treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: optimal treatment
Study: 9608770
Drug: proton pump
Normalized name: Proton pump inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: proton pump inhibitors
Study: 3191018
Drug: EMLA cream
Normalized name: LIDOCAINE 25 mg in 1 g / PRILOCAINE 25 mg in 1 g TOPICAL CREAM [Emla Cream]
DrugBank: Prilocaine (DB00750)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: EMLA cream (eutectic mixture of lignocaine and prilocaine)
Study: 25935831
Drug: Tablet ranitidine,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet ranitidine, 150 mg; and tablet metoclopramide, 10 mg administered the night before and 2 hours before surgery
Study: 24660591
Drug: Hypoglycemic anti-deafness
Normalized name: Anti Bac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypoglycemic anti-deafness capsules
Study: 24660591
Drug: Glibenclamide and
Normalized name: Glibenclamide and metformin only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glibenclamide and conventional drug treatment for deafness
Study: 17023848
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg IV dexamethasone
Study: 17023848
Drug: 80 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg IV dexamethasone
Study: 30845873
Drug: β-Blockers
Normalized name: capsaicin
DrugBank: Capsaicin (DB06774)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: β-Blockers
Study: 14511896
Drug: Renin-angiotensin system
Normalized name: Renin-angiotensin system inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Renin-angiotensin system blockers in combination with diuretics, β-blockers, or calcium channel blockers
Study: 11115810
Drug: Megestrol acetate
Normalized name: Megestrol Acetate
DrugBank: Megestrol (DB19378)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Megestrol acetate (MA) 800 mg/day for 12 weeks
Study: 9314453
Drug: Meningococcal septic
Normalized name: MENINGOCOCCAL B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meningococcal septic shock treatment (specific intervention details not provided)
Study: 8392077
Drug: Metoclopramide (7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoclopramide (7 mg/kg) plus dexamethasone (12 mg)
Study: 3326678
Drug: Meclofenamate sodium
Normalized name: Meclofenamate Sodium
DrugBank: Meclofenamic acid (DB00939)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Meclofenamate sodium 200 mg
Study: 23973155
Drug: Ibuprofen (low
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen (low and high dosages)
Study: 23973155
Drug: Higher dosages
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher dosages of NSAIDs (Celecoxib, Diclofenac, Ibuprofen)
Study: 15985582
Drug: Lamotrigine (LTG)
Normalized name: Lamotrigine
DrugBank: Lamotrigine (DB00555)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lamotrigine (LTG) at a target dose of 300 mg/day
Study: 15985582
Drug: Topiramate (TPM)
Normalized name: Topiramate
DrugBank: Topiramate (DB00273)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Topiramate (TPM) at a target dose of 300 mg/day
Study: 15985582
Drug: Non-drug average
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-drug average
Study: 14664266
Drug: Stabident intraosseous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stabident intraosseous injection
Study: 14664266
Drug: X-tip intraosseous
Approvals — FDA: no, EMA: no, PMDA: no
Description: X-tip intraosseous injection
Study: 1512105
Drug: Ofloxacin (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ofloxacin (300 mg orally, b.i.d.)
Study: 1512105
Drug: Cephalexin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cephalexin (500 mg orally, b.i.d.)
Study: 6361791
Drug: Suprofen 200
Normalized name: suprofen 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suprofen 200 mg q.i.d.
Study: 9625122
Drug: Aspirin 650
Normalized name: aspirin 650 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin 650 mg q.i.d.
Study: 20589317
Drug: Edoxaban 90
Approvals — FDA: no, EMA: no, PMDA: no
Description: Edoxaban 90 mg once daily
Study: 20589317
Drug: Dalteparin (control)
Normalized name: dalteparin
DrugBank: Dalteparin (DB06779)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dalteparin (control) 2,500 IU initial, 5,000 IU subsequent doses once daily
Study: 17521052
Drug: Preventive measures
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preventive measures including fluid volume loading, discontinuation of nephrotoxic medications 48 hours prior to the study, minimizing CM volume and frequency, avoiding high-osmolar contrast in renal impairment, considering iso-osmolar contrast.
Study: 11057351
Drug: Emedastine ophthalmic
Normalized name: emedastine ophthalmic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Emedastine ophthalmic solution 0.05% BID
Study: 11057351
Drug: Levocabastine ophthalmic
Normalized name: levocabastine ophthalmic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levocabastine ophthalmic suspension 0.05% BID
Study: 9376749
Drug: Gidazepam (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gidazepam (20 mg test dose, 40 mg daily, 14-day course)
Study: 9376749
Drug: Phenazepam (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenazepam (0.5 mg and 1 mg test doses, daily dose 2 mg, 14-day course)
Study: 8251874
Drug: Extended cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended cognitive behavioral treatment (CB)
Study: 7018164
Drug: Tinidazole 2
Normalized name: tinidazole 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tinidazole 2 g single oral dose
Study: 23538338
Drug: Low-dose cytarabine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose cytarabine plus daunorubicin and etoposide
Study: 23538338
Drug: High-dose cytarabine
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose cytarabine plus daunorubicin and etoposide
Study: 20659966
Drug: Conservative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative treatment without reduction
Study: 17590313
Drug: Virtual reality
Normalized name: RelieVRx Virtual Reality Behavioral Therapy for Pain Relief
Approvals — FDA: no, EMA: no, PMDA: no
Description: Virtual reality (VR) activity, 2-3 times weekly for 12 weeks using GestureTek's Gesture Xtreme video capture VR system
Study: 16836708
Drug: Cocaine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cocaine (20 mg)
Study: 31593637
Drug: Vitamin D3
Normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D3 supplement at a dose of 50,000 IU/week (n = 23)
Study: 31593637
Drug: CrPic supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: CrPic supplement at a dose of 500 μg/day (n = 23)
Study: 31593637
Drug: Both vitamin
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both vitamin D3 at a dose of 50,000 IU/week and CrPic at a dose of 500 μg/day (n = 23)
Study: 29747625
Drug: Leaflet cluster
Normalized name: cluster fig extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leaflet cluster (oral health education through leaflets)
Study: 29747625
Drug: E-learning cluster
Normalized name: cluster fig extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: E-learning cluster (oral health education through E-learning program)
Study: 27025586
Drug: Endocrine Treatment
Normalized name: ENDOCRINE THERAPY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endocrine Treatment (ET) + Radiotherapy (RAD)
Study: 22418829
Drug: ACT‐077825 (1-1,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACT‐077825 (1-1,000 mg)
Study: 18715218
Drug: 1,000 mg
Normalized name: bran 1,000 mg ORAL WAFER
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1,000 mg of CrPic for 8 weeks
Study: 18715218
Drug: Intraperitoneal administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intraperitoneal administration of CrPic (0, 1, 10, or 50 microg/kg)
Study: 18715218
Drug: Intracerebroventricular administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intracerebroventricular administration of CrPic (0, 0.4, 4, or 40 ng)
Study: 16439811
Drug: Petrolatum-based ointments
Normalized name: PETROLATUM BASE
DrugBank: Petrolatum (DB11058)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Petrolatum-based ointments
Study: 10376614
Drug: Metoprolol CR/XL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol CR/XL 12.5 mg (NYHA III‐IV) or 25.0 mg once daily (NYHA II), target dose 200 mg once daily, up-titrated over 8 weeks
Study: 29211888
Drug: OCP +
Normalized name: Oral Contraceptive Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: OCP + BC (50 mg/d)
Study: 24469526
Drug: Psychodynamic psychotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychodynamic psychotherapy plus adjunctive pharmacotherapy
Study: 22386831
Drug: Celecoxib 400
Normalized name: celecoxib 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celecoxib 400 mg daily
Study: 14502372
Drug: Erythromycin estolate,
Normalized name: Erythromycin Estolate, estolate 250 mg oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythromycin estolate, 20 mg kg‐1 day‐1, divided into four oral doses for 4 weeks
Study: 10732392
Drug: Saw palmetto
Normalized name: Saw palmetto
DrugBank: Saw palmetto (DB14360)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saw palmetto extract (SPE) 160 mg standardized extract twice daily
Study: 1327632
Drug: Liquorice (7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liquorice (7 days of oral administration)
Study: 1327632
Drug: Cortisol (intra-arterial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cortisol (intra-arterial infusion)
Study: 3901992
Drug: Cephamandole (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cephamandole (1 g single dose given 1 hour before surgery)
Study: 3901992
Drug: Cephamandole (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cephamandole (1 g single dose)
Study: 20493567
Drug: Captopril or
Normalized name: captopril Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril or Losartan (not specified dosage or duration)
Study: 16719233
Drug: Rosiglitazone (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosiglitazone (4 to 8 mg daily)
Study: 16719233
Drug: Glibenclamide (3.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glibenclamide (3.5 to 10.5 mg daily)
Study: 11413528
Drug: Postoperative adjuvant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative adjuvant chemotherapy (various protocols including intraarterial and intravenous epirubicin, oral tegafur, carmofur)
Study: 802975
Drug: Anesthetic (sensory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anesthetic (sensory deprivation of the oral cavity via nerve-block injections)
Study: 21467538
Drug: Visionary leaders
Approvals — FDA: no, EMA: no, PMDA: no
Description: Visionary leaders (those who offer novel solutions)
Study: 16575425
Drug: placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo treatment over the left OFC
Study: 2965135
Drug: Teicoplanin 400
Normalized name: Teicoplanin 400 mg powder for solution for injection vial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Teicoplanin 400 mg daily
Study: 2965135
Drug: Vancomycin 1
Normalized name: vancomycin 125 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vancomycin 1 g bd
Study: 24815417
Drug: Diclofenac 0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diclofenac 0.1 mg·kg(‐1) with acetaminophen 40 mg·kg(‐1) before surgery and 20 mg·kg(‐1) rectally at the end of surgery
Study: 24815417
Drug: Diclofenac 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diclofenac 0.5 mg·kg(‐1) with acetaminophen 40 mg·kg(‐1) before surgery and 20 mg·kg(‐1) rectally at the end of surgery
Study: 24815417
Drug: Diclofenac 2.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diclofenac 2.0 mg·kg(‐1) with acetaminophen 40 mg·kg(‐1) before surgery and 20 mg·kg(‐1) rectally at the end of surgery
Study: 24815417
Drug: Diclofenac 0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diclofenac 0.1 mg·kg(‐1) only
Study: 24815417
Drug: Diclofenac 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diclofenac 0.5 mg·kg(‐1) only
Study: 24815417
Drug: Diclofenac 2.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diclofenac 2.0 mg·kg(‐1) only
Study: 24815417
Drug: Acetaminophen 30
Normalized name: acetaminophen 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen 30 mg·kg(‐1)
Study: 22791166
Drug: Risedronate (17.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risedronate (17.5 mg weekly)
Study: 16128676
Drug: Probiotic mixture
Normalized name: brown mixture
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic mixture containing Lactobacillus rhamnosus GG, L. rhamnosus LC705, Bifidobacterium breve Bb99, and Propionibacterium freudenreichii ssp. shermanii JS, taken daily for 6 months.
Study: 16128676
Drug: Placebo capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsule taken daily for 6 months.
Study: 10086942
Drug: Ventstream nebuliser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ventstream nebuliser (MMD, 3.3 microm; delivery rate, 0.075 ml/min)
Study: 10086942
Drug: Optimist nebuliser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optimist nebuliser (MMD, 1.8 microm; delivery rate, 0.02 ml/min)
Study: 7822046
Drug: Live oral
Normalized name: Cholera Vaccine Live Oral
DrugBank: Vibrio cholerae CVD 103-HgR strain live antigen (DB14443)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Live oral cholera vaccine CVD 103-HgR
Study: 2239116
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg 0.5% bupivacaine after free drops of CSF (Group I)
Study: 2239116
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg 0.5% bupivacaine after removal of 3 ml CSF (Group II)
Study: 2239116
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg 0.5% bupivacaine after removal of 5 ml CSF (Group III)
Study: 497087
Drug: Intravenous cyclophosphamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous cyclophosphamide administration
Study: 497087
Drug: Oral cyclophosphamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral cyclophosphamide administration
Study: 497087
Drug: Both intravenous
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both intravenous and oral cyclophosphamide administration
Study: 23378064
Drug: Comparison of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison of Fulvestrant 500 mg to Fulvestrant 250 mg
Study: 21098066
Drug: Control treatment
Normalized name: SALICYLIC ACID 190 mg in 1 mL TOPICAL LIQUID [Derma E Acne Blemish Control Treatment Serum]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control treatment (education session with monthly phone follow-ups)
Study: 1767056
Drug: Iopamidol 150
Normalized name: Iopamidol
DrugBank: Iopamidol (DB08947)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Iopamidol 150 mgI/ml (250 ml)
Study: 1767056
Drug: Iopamidol 370
Normalized name: iopamidol 370 mg iodine/mL (76 %) INTRAVEN KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iopamidol 370 mgI/ml (100 ml)
Study: 6120311
Drug: Slow-release aminophylline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Slow-release aminophylline (mean 683 mg; 10.4 mg/kg)
Study: 31980342
Drug: Control for
Normalized name: Anti Acne Control Formula Top
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control for neurocognition, antipsychotic medication, and depressive symptoms
Study: 28688269
Drug: Horticulture therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Horticulture therapy in specially designed urban green environments
Study: 28688269
Drug: Occupational art
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Occupational art therapy (control group)
Study: 25577543
Drug: Montelukast (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Montelukast (10 mg) with budesonide (400 µg)
Study: 25577543
Drug: Doxofylline (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxofylline (400 mg) with budesonide (400 µg)
Study: 25577543
Drug: Tiotropium (18
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiotropium (18 µg) with budesonide (400 µg)
Study: 25577543
Drug: Formoterol (12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formoterol (12 µg) with budesonide (400 µg)
Study: 17215602
Drug: Programmed Information
Normalized name: Inflammation OTC Bruise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Programmed Information for Parental Coping before Intravenous Procedure (PIPC‐IP)
Study: 14653130
Drug: Ginkgo Biloba
Normalized name: Ginkgo Biloba
DrugBank: Ginkgo biloba (DB01381)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ginkgo Biloba capsule
Study: 11015996
Drug: Oral 5'-DFUR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral 5'-DFUR (610 mg/m2/day x 10 days or over) preoperatively
Study: 11015996
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment preoperatively (Group II)
Study: 11015996
Drug: Oral 5'-DFUR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral 5'-DFUR (good compliance)
Study: 11015996
Drug: Oral 5'-DFUR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral 5'-DFUR (poor compliance)
Study: 9165564
Drug: Mycophenolate mofetil
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mycophenolate mofetil 1500 mg orally
Study: 9165564
Drug: Ganciclovir 5
Normalized name: ganciclovir 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ganciclovir 5 mg/kg intravenously
Study: 1350482
Drug: Carvedilol 12.5
Normalized name: carvedilol 12.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carvedilol 12.5 mg daily
Study: 1350482
Drug: Carvedilol 25
Normalized name: carvedilol 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carvedilol 25 mg daily
Study: 1350482
Drug: Carvedilol 6.25
Normalized name: carvedilol 6.25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carvedilol 6.25 mg daily
Study: 4001280
Drug: Desimipramine (DMI)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desimipramine (DMI) 25 mg
Study: 4001280
Drug: Desimipramine (DMI)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desimipramine (DMI) 15 mg
Study: 29197219
Drug: 0.05 mg/kg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.05 mg/kg/day of somatropin
Study: 26935819
Drug: Sarolaner (Simparica™)
Normalized name: sarolaner Chewable Tablet [Simparica]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sarolaner (Simparica™) at a minimum dose of 2 mg/kg
Study: 25355697
Drug: Monthly or
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monthly or bimonthly standard 3-day treatment regimens of dihydroartemisinin-piperaquine
Study: 25355697
Drug: Monthly dosing
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Monthly dosing regimen based on the final model
Study: 20888520
Drug: Testosterone transdermal
Normalized name: testosterone Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: Testosterone transdermal patch (T group, n = 24)
Study: 12744768
Drug: Linezolid (intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Linezolid (intravenous followed by optional oral)
Study: 12744768
Drug: Vancomycin (intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vancomycin (intravenous only)
Study: 12201213
Drug: Antithyroid treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antithyroid treatment (Group 1)
Study: 7056011
Drug: Oral metaproterenol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral metaproterenol for four weeks
Study: 7056011
Drug: Oral theophylline
Normalized name: theophylline Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral theophylline for four weeks
Study: 26924470
Drug: eOIT (egg
Approvals — FDA: no, EMA: no, PMDA: no
Description: eOIT (egg oral immunotherapy)
Study: 3266277
Drug: Pulsed electromagnetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pulsed electromagnetic field (PEMF) treatment
Study: 22085872
Drug: Enalapril-FA tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril-FA tablet (10 mg enalapril combined with 0.8 mg of FA, high FA group)